There is limited clinical experience of overdose of Anastrozole (ARIMIDEX). There are no reports where a patient has taken a dose excessing 60 mg. No toxicity was observed and no clinically relevant adverse effects have been seen.
Acute toxicity was seen in animals at a dose greater than 45 mg/kg (equivalent to 2.7 g). Clinical trials have been conducted with various dosages of Anastrozole (ARIMIDEX), up to 60 mg in a single dose given to healthy male volunteers and up to 10 mg daily given to postmenopausal women with advanced breast cancer; these dosages were well tolerated. A single dose of Anastrozole (ARIMIDEX) that results in life threatening symptoms has not been established.
There is no specific antidote to over dosage and treatment must be symptomatic. In the management of an overdose, consideration should be given to the possibility that multiple agents may have been taken. Vomiting may be induced if the patient is alert. Dialysis may be helpful because Anastrozole (ARIMIDEX) is not highly protein bound. General supportive care, including frequent monitoring of vital signs and close observation of the patient, is indicated.